Clinical efficacy of valproic acid in relation to plasma levels.
Valproic acid is a new antiepileptic drug recently introduced in the United States for the treatment of absence seizures. In this study on patients with absence and other seizure types, the majority of patients achieved optimal control within four weeks of therapy. No patient responded to valproic acid who did not show an initial clinical response by four weeks of active therapy. Optimal response was generally achieved when plasma levels were greater than 55 microgram/ml. Excellent clinical response was observed in the treatment of absence and myoclonic seizures. Twenty-two patients continued in a long term study have maintained the same degree of seizure control as observed at the time of optimal control.
D000293:Adolescent; D000328:Adult; D004831:Epilepsies, Myoclonic / Q000188:drug therapy; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy*; D004832:Epilepsy, Absence / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D014635:Valproic Acid / Q000008:administration & dosage* / Q000097:blood / Q000627:therapeutic use
D014635:Valproic Acid